Toron Capital Markets Inc increased Johnson & Johnson (JNJ) stake by 2.95% reported in 2017Q3 SEC filing. Toron Capital Markets Inc acquired 5,292 shares as Johnson & Johnson (JNJ)’s stock rose 6.85%. The Toron Capital Markets Inc holds 184,431 shares with $23.98M value, up from 179,139 last quarter. Johnson & Johnson now has $395.89B valuation. The stock increased 0.30% or $0.44 during the last trading session, reaching $147.36. About 8.74 million shares traded or 58.03% up from the average. Johnson & Johnson (NYSE:JNJ) has risen 12.54% since January 21, 2017 and is uptrending. It has underperformed by 4.16% the S&P500.
Abaxis, Inc. develops, manufactures, markets, and sells portable blood analysis systems for use in human or veterinary patient care settings to provide rapid blood constituent measurements for clinicians worldwide. The company has market cap of $1.39 billion. It operates in two divisions, Medical Market and Veterinary Market. It has a 51.39 P/E ratio. The firm offers Piccolo chemistry analyzers with rapid blood constituent measurements for use in human patient care; and Piccolo profiles that are single-use medical reagents.
Among 23 analysts covering Johnson & Johnson (NYSE:JNJ), 12 have Buy rating, 5 Sell and 6 Hold. Therefore 52% are positive. Johnson & Johnson had 86 analyst reports since August 7, 2015 according to SRatingsIntel. The firm earned “Buy” rating on Wednesday, April 20 by Argus Research. The firm earned “Buy” rating on Monday, October 23 by Citigroup. The rating was downgraded by JP Morgan to “Neutral” on Tuesday, January 2. Atlantic Securities initiated Johnson & Johnson (NYSE:JNJ) rating on Friday, December 18. Atlantic Securities has “Neutral” rating and $95 target. The stock of Johnson & Johnson (NYSE:JNJ) earned “Hold” rating by Jefferies on Friday, June 16. The stock has “Hold” rating by Stifel Nicolaus on Tuesday, July 18. BMO Capital Markets maintained the stock with “Buy” rating in Monday, July 10 report. The firm has “Hold” rating by Piper Jaffray given on Tuesday, July 18. The stock of Johnson & Johnson (NYSE:JNJ) has “Buy” rating given on Wednesday, October 18 by Argus Research. The firm has “Buy” rating given on Wednesday, October 18 by RBC Capital Markets.
Toron Capital Markets Inc decreased Canadian Pac Ry Ltd (NYSE:CP) stake by 71,500 shares to 492,365 valued at $82.48 million in 2017Q3. It also reduced Celestica Inc (NYSE:CLS) stake by 78,800 shares and now owns 2.13M shares. Credicorp Ltd (NYSE:BAP) was reduced too.
Investors sentiment is 0.83 in Q3 2017. Its the same as in 2017Q2. It is the same, as 45 investors sold JNJ shares while 871 reduced holdings. only 111 funds opened positions while 645 raised stakes. 1.71 billion shares or 0.90% less from 1.73 billion shares in 2017Q2 were reported. Sage Fincl Gp reported 1,598 shares. Toronto Dominion Savings Bank reported 1.36 million shares. First Bancorp Sioux Falls stated it has 7,328 shares. Marshall Wace Llp reported 0.09% of its portfolio in Johnson & Johnson (NYSE:JNJ). The New York-based Mufg Americas Corporation has invested 1.51% in Johnson & Johnson (NYSE:JNJ). Moon Cap Mgmt Limited Liability Corp holds 0.97% in Johnson & Johnson (NYSE:JNJ) or 6,459 shares. Neumann Mngmt Llc invested in 1.68% or 20,850 shares. Fmr Ltd Limited Liability Company reported 0.4% of its portfolio in Johnson & Johnson (NYSE:JNJ). 77,691 were reported by Motco. 157,166 were reported by Counselors. Indiana-based First Financial In has invested 0.71% in Johnson & Johnson (NYSE:JNJ). Stoneridge Llc accumulated 181,007 shares. Amer Money Limited Liability Company reported 2.61% of its portfolio in Johnson & Johnson (NYSE:JNJ). Laffer Invests holds 0.21% in Johnson & Johnson (NYSE:JNJ) or 6,086 shares. Peavine Limited Liability has 0.17% invested in Johnson & Johnson (NYSE:JNJ) for 2,340 shares.
Ratings analysis reveals 0 of Abaxis’s analysts are positive. Out of 2 Wall Street analysts rating Abaxis, 0 give it “Buy”, 0 “Sell” rating, while 2 recommend “Hold”. ABAX was included in 2 notes of analysts from November 30, 2016. The stock has “Hold” rating by Stifel Nicolaus on Friday, January 27. On Wednesday, November 30 the stock rating was downgraded by Northcoast to “Neutral”.
The stock increased 0.58% or $0.35 during the last trading session, reaching $61.16. About 144,591 shares traded. Abaxis, Inc. (ABAX) has risen 7.18% since January 21, 2017 and is uptrending. It has underperformed by 9.52% the S&P500.
Analysts await Abaxis, Inc. (NASDAQ:ABAX) to report earnings on January, 25. They expect $0.23 earnings per share, down 23.33% or $0.07 from last year’s $0.3 per share. ABAX’s profit will be $5.22 million for 66.48 P/E if the $0.23 EPS becomes a reality. After $0.29 actual earnings per share reported by Abaxis, Inc. for the previous quarter, Wall Street now forecasts -20.69% negative EPS growth.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.